All News
FDA recently approved - fms-like tyrosine kinase 1 (s-Flt1) / placental growth factor (PlGF), for diagnosing preeclampsia.
sFlt1:PlGF≤38 rules out preeclampsia in SLE
sFlt1:PlGF>85 modestly predicts preeclampsia
Proteinuria impacts prediction accuracy #ACR24 abst#0809 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Nationwide US study
-Prevalence of HLH in SLE: 0.13%
-Higher risk in younger, female, and racial minority patients
- Strong association with high mortality #ACR24 abst#0619 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Study on #AI-augmented remote care for SLE:
- Combined biometric, self-reported, and NLP-extracted data
- Moderate to strong correlations with physician global assessment
- Potential to improve remote disease management - but now very accurate for now
#ACR24 abst#0635 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Interim analysis of a Phase 4 study of ARD (RA 25%, SLE 25%) patients shows recombinant herpes zoster vaccine(RZV) good safety profile, with no impact on disease activity (flare rates: 13.6% vs. 12.4%). Immunogenicity: 93% response in ARDs vs. 99% in controls. Rituximab & MMF… https://t.co/U3s48fLduX https://t.co/WTvD5shtXB
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Study on socioeconomic factors in SLE hospitalizations - US wide data
- No insurance & non-metro areas linked to shorter LOS, lower costs, higher mortality
- Higher income & age increase charges
- Targeted interventions needed to improve outcomes
#ACR24 abst#0615 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Study on pregnancy outcome disparities in SLE:
- Analyzed 685 women, 1888 pregnancies
- Pre-SLE state linked to fewer live births, higher preeclampsia risk
- Outcomes worse post-SLE diagnosis
#ACR24 abst#0440 @RheumNow https://t.co/NpEYQZ73uo
Links:
Bella Mehta bella_mehta ( View Tweet)
Briefly highlighting this poster, always looking for a non-Georg Schett CAR-T study to see if their results replicate
All 10 pts in this one had a "complete humoral response," normalizing antibodies & experiencing long term drug-free remission
#ACR24 @RheumNow Abstr#0673 https://t.co/pjOjRnJVhO
Mike Putman EBRheum ( View Tweet)
This poster makes me happy for so many reasons 😆
Aggressive & descriptive title? ☑️
Pretty chloropleth map? ☑️
Dunks on hamfisted EMR tools trying to replace patient-physician interactions? ☑️
@RheumNow #ACR24 Abstr#0668 ThereAreNoShortcuts https://t.co/IXYaHAi15q
Mike Putman EBRheum ( View Tweet)
This is likely an oversimplification, but I've been looking for exactly this diagram
Inhibiting various TYKs/JAKs corresponds to various downstream cytokine inhibition
@EricFMorand does it make sense to see this as anifrolumab+ustekinumab? No?
@rheumnow #ACR24 Abstr#0662 https://t.co/thti6s5TR3
Links:
Mike Putman EBRheum ( View Tweet)
Ok so trivial tweet here but I just love the name of this outcome measure... "LFA-REAL" 😄😆
Serious topic though; PRO's are huge in SLE research!
@RheumNow #ACR24 Abstr#0626 https://t.co/w34zTNjSbH
Mike Putman EBRheum ( View Tweet)
🧬 #SLE patients show major community mobility limits: 50% don't leave their neighborhood weekly without help. Life Space Assessment finds lower mobility vs. other chronic conditions. Better mobility linked to higher SES & lower disease activity. @RheumNow #ACR24 abst#0145 https://t.co/2sfXNlJ9JD
Bella Mehta bella_mehta ( View Tweet)
Shu et al. Rituximab followed by Telitacicept in refractory/severe APS. Significantly fewer new clinical events in Telitacicept group over 24 weeks (1/21 vs. 6/20) @RheumNow #ACR24 Abstr#0129 https://t.co/hjUQkNNk5w https://t.co/QLQbZ3wQx0
Links:
Richard Conway RichardPAConway ( View Tweet)
🔍 Study on lupus & APS highlights key links! APS patients face higher rates of developing SLE, and vice versa. Notable predictors: females, lupus anticoagulant, and specific antibodies. These insights stress the need for vigilant monitoring in both. #ACR24 @RheumNow Abst#0119
Bella Mehta bella_mehta ( View Tweet)
Prevalence of HLH among pts w/SLE: lower than consults would suggest!
Observational study using NIS: 139 cases out of >100k pts w/SLE (0.13%); 6 fold increase in mortality
Fits my priors; HLH is overdiagnosed, but bad when it happens
@RheumNow #ACR24 Abstr#0619 https://t.co/iz3BlUOJb9
Mike Putman EBRheum ( View Tweet)
#Abstract0649
Acetylated albumin at K402 as a possible predictor for newly diagnosed lupus nephritis, distinguishing incident LN from SLE, treated LN & healthy controls.
@RheumNow #ACR24 https://t.co/aCRzt9TtoK
Akhil Sood MD AkhilSoodMD ( View Tweet)
Another abstract #0650 highlighting the impact of tubulointerstitial inflammation predicting risk of CKD/ESRD in lupus nephritis
@RheumNow #ACR24 https://t.co/XYwO0xnWNR
Akhil Sood MD AkhilSoodMD ( View Tweet)
Discrimination in #SLE is a chronic stressor - Asians had substantial levels along with association of worse mental health and SLE activity
Data from the California Lupus Epidemiology Study (CLUES) using the Everyday Discrimination Scale (EDS) @JYazdany @RheumNow #ACR24 abst#0171
Bella Mehta bella_mehta ( View Tweet)
Cardiology 🤝 Rheumatology
#Abstract0611 highlights Subclinical atherosclerosis (carotid plaque > 1.5 mm) associated with ↑ risk of CV events in SLE longitudinal cohort
@RheumNow #ACR24 https://t.co/jLLYNOfFZ2
Akhil Sood MD AkhilSoodMD ( View Tweet)
Can PROs help identify high-risk #SLE patients? #Abstract0655 from the FORWARD registry shows higher SLAQ scores (including flares) and RDCI are linked to increased hospitalization risk.
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abstr#0647
Toronto Lupus Clinic finds pericarditis in 20% of #SLE inception cohort, often with skin, heme, MSK, & renal involvement. Linked to younger age, White race, +SSB, & lower ACR/EULAR scores
- Tx: GC, HCQ, AZA
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
